Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Cor Therapeutics Inc. (CORR) -- Ignore unavailable to you. Want to Upgrade?

To: Biomaven who wrote (445)	5/12/1999 2:59:00 PM
From: John Patterson	Read Replies (1) \| Respond to of 712

I agree with you Peter, bleeding has not been a major problem with ReoPro, at least not for the cardiologist. However, the bleeding associated with emergency open-heart surgery can be significant. Many of the patients that we receive after failed angioplasty, and/or stenting have been on asprin at home, have had heparin during their cath, received TPA in the ER and then ReoPro in an attempt to keep the artery patent. These patients may require multiple transfusions of RBC's, platlets, and fresh frozen plasma in addition to a host of drugs such as DDAVP, Aprotinin, Amicar and protamine in an attempt to restore hemostasis. Of course, the effect of Integrillin on platlet adhesion is profound also.